News

You heard it here first.

 
 
 

Our news

Bringing you the latest!

All news

MedinCell has launched a COVID-19 research initiative based on its experience to formulate long-acting injectable Ivermectin

Corporate - Investors

6 April 2020

Publication of the activity report and financial information for the first half-year (April – Sept. 2019)

Investors

3 December 2019

 
 

Press

Communication leader
MedinCell
David Heuzé
david.heuze@medincell.com
+33 (0)6 83 25 21 86

Media
NewCap
Nicolas Merigeau
medincell@newcap.eu
+33 (0)1 44 71 94 94

Investors

Investors website

Investor Relations
NewCap
Louis-Victor Delouvrier /
Alexia Faure

medincell@newcap.eu
+33 (0)1 44 71 94 94

CONTACT

  • This field is for validation purposes and should be left unchanged.